Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
Francisco M. Marty(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), John Koreth(Otsuka (Japan)), Vincent T. Ho(Dana-Farber Cancer Institute), Sarah Browne(National Institute of Allergy and Infectious Diseases), Joseph H. Antin(Boston University), Ingrid V. Bassett(Apple (Israel)), Robert J. Soiffer(Harvard University), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Talya Schwarzberg(Harvard University), Julie M. Bryar(Harvard University), Corey Cutler(Harvard University)
Cited by 142
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k